Autologous T Cell Therapy for MAGE-A4⁺ Solid Cancers in HLA-A^*02⁺ Patients: A Phase 1 Trial

Researchers conducted a multicenter, dose-escalation, phase 1 trial in patients with relapsed/refractory metastatic solid tumors expressing MAGE-A4, including synovial sarcoma, ovarian cancer and head and neck cancer.